Article ; Online: Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial.
2002 Volume 137, Issue 9, Page(s) 726–733
Abstract: Background: Disease-modifying antirheumatic drugs may confer greater benefits when combined with the antimetabolite methotrexate.: Objective: To evaluate the efficacy and safety of leflunomide versus placebo when added to ongoing, stable-dose ... ...
| Abstract | Background: Disease-modifying antirheumatic drugs may confer greater benefits when combined with the antimetabolite methotrexate. Objective: To evaluate the efficacy and safety of leflunomide versus placebo when added to ongoing, stable-dose methotrexate therapy in patients with persistently active rheumatoid arthritis. Design: 24-week, multicenter, randomized, double-blind, placebo-controlled trial. Setting: 20 centers in the United States and Canada. Patients: Patients with persistent rheumatoid arthritis, as defined by American College of Rheumatology (ACR) criteria, despite receiving methotrexate for at least 6 months. Intervention: Leflunomide or matching placebo added to existing methotrexate therapy. Measurements: The primary efficacy variable was the rate of achievement of 20% improvement in ACR criteria (ACR20) at the end of the study. The Health Assessment Questionnaire Disability Index was assessed at each visit, and the Medical Outcomes Study 36-Item Short Form was completed as an end point analysis. Results: In the leflunomide and placebo groups, 46.2% and 19.5% of patients, respectively, met ACR20 criteria at 24 weeks (P < 0.001). Clinical improvement was demonstrated by statistically significant mean changes in individual components of the ACR20 response criteria. Discontinuation rates were similar in both treatment groups (23.1% in the leflunomide group and 24.8% in the placebo group), as were the overall incidences of adverse events (89.2% vs. 89.5%, respectively). Adverse events were predominantly mild or moderate. Conclusions: Combination therapy with leflunomide and methotrexate provides statistically significant clinical benefit in patients with active rheumatoid arthritis who are receiving methotrexate therapy. Leflunomide plus methotrexate is generally well tolerated and can be used safely with appropriate liver enzyme and hematologic monitoring. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Adult ; Aged ; Anti-Inflammatory Agents, Non-Steroidal/adverse effects ; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Antimetabolites/adverse effects ; Antimetabolites/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Diarrhea/chemically induced ; Disability Evaluation ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Humans ; Isoxazoles/therapeutic use ; Leflunomide ; Liver Function Tests ; Male ; Methotrexate/adverse effects ; Methotrexate/therapeutic use ; Middle Aged ; Placebos ; Quality of Life ; Surveys and Questionnaires ; Treatment Outcome | |||||
| Chemical Substances | Anti-Inflammatory Agents, Non-Steroidal ; Antimetabolites ; Isoxazoles ; Placebos ; Leflunomide (G162GK9U4W) ; Methotrexate (YL5FZ2Y5U1) | |||||
| Language | English | |||||
| Publishing date | 2002-11-05 | |||||
| Publishing country | United States | |||||
| Document type | Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't | |||||
| ZDB-ID | 336-0 | |||||
| ISSN | 1539-3704 ; 0003-4819 | |||||
| ISSN (online) | 1539-3704 | |||||
| ISSN | 0003-4819 | |||||
| DOI | 10.7326/0003-4819-137-9-200211050-00007 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Ua VI Zs.178/2: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.